NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.
Frequently asked questions
What sector does NervGen Pharma Corp (NGEN) operate in?
NervGen Pharma Corp belongs to the Healthcare sector and operates in the Biotechnology industry.
What is NervGen Pharma Corp (NGEN) current stock price?
As of the latest data, NervGen Pharma Corp stock price is CA$5.15, with a previous close of CA$5.15.
What is NervGen Pharma Corp (NGEN) current market capitalization?
NervGen Pharma Corp market cap is approximately 407.94 million.
What is NervGen Pharma Corp (NGEN) Earnings Per Share (EPS)?
The trailing EPS is -CA$0.36, and the forward EPS is -CA$0.26.
Does NervGen Pharma Corp (NGEN) pay dividends?
No. NervGen Pharma Corp does not pay a dividend.
What is NervGen Pharma Corp (NGEN) beta (volatility) score?
NervGen Pharma Corp has a beta of 0.861, meaning its volatility is roughly in line with the market.
